Tags

Type your tag names separated by a space and hit enter

In vitro antimicrobial activity and MIC quality control guidelines of RPR 106972 (RPR 112808/RPR106950): a novel orally administered streptogramin combination. The Quality Control Study Group.
Diagn Microbiol Infect Dis. 1997 Jul; 28(3):139-47.DM

Abstract

RPR 106972 is a novel oral streptogramin combination with reported therapeutic potency against Gram-positive and certain respiratory tract pathogens. MICs for RPR 106972, quinupristin/dalfopristin, and seven comparison drugs were determined by the reference methods against 337 strains selected to define spectrum and potency. RPR 106972 demonstrated antimicrobial activity against oxacillin-susceptible and -resistant Staphylococcus aureus (MIC ranges of 0.12 to 2 micrograms/ml and 0.5 to 2 micrograms/ml, respectively), and coagulase-negative staphylococci were also inhibited by RPR 106972 (MIC90, < or = 0.5 microgram/ml) and quinupristin/dalfopristin (MIC90, < or = 0.25 microgram/ml). Against all streptococcal strains tested (including penicillin-resistant pneumococcus), RPR 106972 was highly active with MIC results at < or = 1 microgram/ml. RPR 106972 inhibited Corynebacterium jeikeium (MIC90, 0.5 microgram/ml). Moraxella catarrhalis (MIC90, 0.25 microgram/ml), and some Haemophilus influenzae (MIC50, 2 micrograms/ml). RPR 106972 and quinupristin/dalfopristin demonstrated little activity against Enterococcus faecalis (MIC90s, 4 to 32 micrograms/ml) as compared to Enterococcus faecium (MIC90s, 0.5 to 1 microgram/ml) and other Enterococcus ssp. (MIC90s, 1 microgram/ml). Studies to establish MIC quality-control guidelines indicated the following ranges: for E. faecalis ATCC 29212, 0.5 to 4 micrograms/ml; for S. aureus ATCC 29213, 0.25 to 1 microgram/ml; and for Streptococcus pneumoniae ATCC 49619, 0.06 to 0.5 microgram/ml. The results of this study indicate that the in vitro activity of RPR 106972 against Gram-positive bacteria and selected Gram-negative respiratory organisms is promising and warrants additional studies of pharmacokinetics, and in vivo infection model dynamics.

Authors+Show Affiliations

Department of Preventive Medicine and Environmental Health, University of Iowa College of Medicine, Iowa City 52242, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

9294704

Citation

Putnam, S D., et al. "In Vitro Antimicrobial Activity and MIC Quality Control Guidelines of RPR 106972 (RPR 112808/RPR106950): a Novel Orally Administered Streptogramin Combination. the Quality Control Study Group." Diagnostic Microbiology and Infectious Disease, vol. 28, no. 3, 1997, pp. 139-47.
Putnam SD, Jones RN, Johnson DM. In vitro antimicrobial activity and MIC quality control guidelines of RPR 106972 (RPR 112808/RPR106950): a novel orally administered streptogramin combination. The Quality Control Study Group. Diagn Microbiol Infect Dis. 1997;28(3):139-47.
Putnam, S. D., Jones, R. N., & Johnson, D. M. (1997). In vitro antimicrobial activity and MIC quality control guidelines of RPR 106972 (RPR 112808/RPR106950): a novel orally administered streptogramin combination. The Quality Control Study Group. Diagnostic Microbiology and Infectious Disease, 28(3), 139-47.
Putnam SD, Jones RN, Johnson DM. In Vitro Antimicrobial Activity and MIC Quality Control Guidelines of RPR 106972 (RPR 112808/RPR106950): a Novel Orally Administered Streptogramin Combination. the Quality Control Study Group. Diagn Microbiol Infect Dis. 1997;28(3):139-47. PubMed PMID: 9294704.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - In vitro antimicrobial activity and MIC quality control guidelines of RPR 106972 (RPR 112808/RPR106950): a novel orally administered streptogramin combination. The Quality Control Study Group. AU - Putnam,S D, AU - Jones,R N, AU - Johnson,D M, PY - 1997/7/1/pubmed PY - 1997/9/19/medline PY - 1997/7/1/entrez SP - 139 EP - 47 JF - Diagnostic microbiology and infectious disease JO - Diagn Microbiol Infect Dis VL - 28 IS - 3 N2 - RPR 106972 is a novel oral streptogramin combination with reported therapeutic potency against Gram-positive and certain respiratory tract pathogens. MICs for RPR 106972, quinupristin/dalfopristin, and seven comparison drugs were determined by the reference methods against 337 strains selected to define spectrum and potency. RPR 106972 demonstrated antimicrobial activity against oxacillin-susceptible and -resistant Staphylococcus aureus (MIC ranges of 0.12 to 2 micrograms/ml and 0.5 to 2 micrograms/ml, respectively), and coagulase-negative staphylococci were also inhibited by RPR 106972 (MIC90, < or = 0.5 microgram/ml) and quinupristin/dalfopristin (MIC90, < or = 0.25 microgram/ml). Against all streptococcal strains tested (including penicillin-resistant pneumococcus), RPR 106972 was highly active with MIC results at < or = 1 microgram/ml. RPR 106972 inhibited Corynebacterium jeikeium (MIC90, 0.5 microgram/ml). Moraxella catarrhalis (MIC90, 0.25 microgram/ml), and some Haemophilus influenzae (MIC50, 2 micrograms/ml). RPR 106972 and quinupristin/dalfopristin demonstrated little activity against Enterococcus faecalis (MIC90s, 4 to 32 micrograms/ml) as compared to Enterococcus faecium (MIC90s, 0.5 to 1 microgram/ml) and other Enterococcus ssp. (MIC90s, 1 microgram/ml). Studies to establish MIC quality-control guidelines indicated the following ranges: for E. faecalis ATCC 29212, 0.5 to 4 micrograms/ml; for S. aureus ATCC 29213, 0.25 to 1 microgram/ml; and for Streptococcus pneumoniae ATCC 49619, 0.06 to 0.5 microgram/ml. The results of this study indicate that the in vitro activity of RPR 106972 against Gram-positive bacteria and selected Gram-negative respiratory organisms is promising and warrants additional studies of pharmacokinetics, and in vivo infection model dynamics. SN - 0732-8893 UR - https://www.unboundmedicine.com/medline/citation/9294704/In_vitro_antimicrobial_activity_and_MIC_quality_control_guidelines_of_RPR_106972__RPR_112808/RPR106950_:_a_novel_orally_administered_streptogramin_combination__The_Quality_Control_Study_Group_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0732889397000230 DB - PRIME DP - Unbound Medicine ER -